The theme of EAPM’s 2nd Bridging Presidency conference, during the auspices of the Slovenia Presidency of the EU, will be “Innovation, Public Trust and Evidence: Generating Alignment to facilitate personalized Innovation in Health Care.” High-level speakers and attendees will come from a wide range of stakeholder groups including patients, healthcare professionals, academics, industry representatives, politicians and legislators, the media and more.
The EAMP conference takes place on 1 July 2021. EAPM, European Alliance for Personalised Medicine, is a HARMONY Partner.
About session 4 of the EAPM Conference | 1 July starting at 14:00 hrs CEST
Increased molecular understanding is transforming the prospects for health care, and molecular diagnostics are opening the pathway to a shift in healthcare strategy. Molecular testing has informed some major preventative public health strategies – such as the significant reduction in cancer mortality. This is the threshold of a new future in which emphasis will shift away from treating illness and move toward maintaining the health of the individual. Early diagnosis and personalised healthcare will have a central part to play, particularly in the cancer arena. The objective for all stakeholders should be to see discovery ‘hits’ translated into robust but affordable clinical ‘wins’ for patients.
#BigDataforbloodcancer | Big Data accelerate better and faster treatment for Blood Cancer Patients
The HARMONY Alliance is a European Public–Private Partnership for Big Data in Hematology that is capturing and mining Big Data on Hematologic Malignancies. Both projects of the HARMONY Alliance, HARMONY and HARMONY PLUS, are funded by the Innovatie Medicines Initiative (IMI). HARMONY unites more than 100 organizations from 18 European countries, such as medical associations, hospitals, research institutes, patient organizations, pharmaceutical and IT companies.
HARMONY uses Big Data analytics to accelerate the development of more effective treatments for blood cancer patients. Data are stored in HARMONY’s Big Data Platform, which has already identified over 70,000 anonymized patient records, making it one of the largest databases of its kind. Leading research teams are currently using this wealth of information to answer critical questions about Blood Cancers / Hematologic Malignancies that cannot be addressed with other methods. This is the added value HARMONY will bring to precision medicine for patients.
Interested in receiving a copy of the HARMONY Policy Paper? Send an email to Ellen de Waal, HARMONY Communications >
More about the HARMONY Alliance: watch the video >
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
